Wave Life Sciences News

Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor

GlobeNewswireMay 2 20:30

Wave Life Sciences' WVE-006 Advancements: A Buy Rating on Gene Editing Innovations and Strategic Partnerships

TipRanksMay 2 15:20

Buy Rating Affirmed: Wave Life Sciences's Promising Future With Clinical Milestones and Strategic GSK Partnership

TipRanksMay 2 14:18

Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, and Iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.4

Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. , Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.45%, and Alexis fell 6.54

Zhitong FinanceMay 2 04:55

Analysts' Top Healthcare Picks: AbbVie (ABBV), Wave Life Sciences (WVE)

TipRanksApr 29 19:53

Buy Rating Affirmed: Strategic Partnerships and Clinical Milestones Propel Wave Life Sciences' Growth Potential

TipRanksApr 26 14:16

Wave Life Sciences: A Promising Buy Rating Based on Strategic GSK Collaboration and Innovative SiRNA Platform

TipRanksApr 26 14:11

Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug

Seeking AlphaApr 23 22:29

As Part Of Wave Life Sciences' Ongoing Collaboration With GSK, GSK Has Selected Its First Two Oligonucleotide Programs, GSK Will Provide An Initiation Payment Of $12M

GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave's next generation GalNA

BenzingaApr 23 22:22

Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in SiRNA and RNA Editing

GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave's next generation GalNAc-siRNA format with

GlobeNewswireApr 23 20:30

We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after l

Simply Wall StApr 9 18:50

Wave Life Sciences(WVE.US) Officer Sells US$96,421.47 in Common Stock

$Wave Life Sciences(WVE.US)$ Officer Moran Kyle sold 15,630 shares of Common Stock on Apr 3, 2024 at an average price of $6.169 for a total value of $96,421.47.Source: Announcement What is statement o

Futu NewsApr 6 08:42

GRIN, WOOF and MRNS Are Among After Hour Movers

Seeking AlphaApr 5 05:29

12 Health Care Stocks Moving In Thursday's After-Market Session

GainersOrgenesis (NASDAQ:ORGS) shares increased by 8.5% to $0.63 during Thursday's after-market session. The company's market cap stands at $21.4 million. AN2 Therapeutics (NASDAQ:ANTX) shares increas

BenzingaApr 5 04:31

Wave Life Sciences Price Target Maintained With a $17.00/Share by Truist Securities

Wave Life Sciences Price Target Maintained With a $17.00/Share by Truist Securities

Dow JonesApr 1 21:18

Analysts' Top Healthcare Picks: Wave Life Sciences (WVE), Passage Bio (PASG)

TipRanksApr 1 19:21

Truist Financial Reaffirms Their Buy Rating on Wave Life Sciences (WVE)

TipRanksApr 1 19:21

Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health,

GlobeNewswireMar 27 20:30

Wave Life Sciences Is Maintained at Buy by Mizuho

Wave Life Sciences Is Maintained at Buy by Mizuho

Dow JonesMar 12 20:00

Mizuho Maintains Buy on WAVE Life Sciences, Raises Price Target to $19

Mizuho analyst Salim Syed maintains WAVE Life Sciences with a Buy and raises the price target from $10 to $19.

Analyst UpgradesMar 12 19:50